|Brand name(s), other common name(s)||DTIC-Dome®|
|Drug type||DNA-damaging agent|
|How the drug is given||Intravenously (IV)|
Dacarbazine is FDA approved to treat people who have Hodgkin lymphoma as a second-line therapy when used in combination with other agents and is also used as initial therapy for some patients with Hodgkin lymphoma. It may cause a temporary loss of hair in some people. After treatment with dacarbazine has ended, normal hair growth should return.
Side effects needing medical attention:If dacarbazine accidentally seeps out of the vein, it may damage some tissues and cause scarring. Your healthcare provider should be notified right away if redness, pain or swelling is noticed at the IV site. Other side effects needing medical attention are: Fever; chills; sore throat; unusual bleeding or bruising; sores in mouth and on lips; black, tarry stools; blood in urine or stool; lower back, side or stomach pain; painful or difficult urination; pinhead-sized red spots on skin; shortness of breath; swelling of face; yellow eyes; loss of appetite; nausea or vomiting (should lessen after 1 or 2 days); flushing or muscle numbness in face.
Side effects needing medical attention after stopping this medication: Fever; chills; sore throat; unusual bleeding or bruising; black, tarry stools; blood in urine or stool; cough; lower back or side pain; painful or difficult urination; pinhead-sized red spots on skin.